HR Execs on the Move


 
Radlink, Inc. is a Redondo Beach, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Advanced Cardiac Therapeutics Inc

Advanced Cardiac Therapeutics, Inc. is a pre-commercial, medical device company that designs and manufactures a catheter-based system for the treatment of patients with AFIB. AFIB is characterized by an irregular, often rapid heart rate that commonly causes poor systemic blood flow. The Company`s mission is to dramatically improve the treatment of AFIB through the introduction of products based on its proprietary catheter and generator system. ACT`s technology is the only system in the world to leverage feedback from four unique capabilities: temperature sensing, low irrigation flow rates, high resolution EGM attenuation and contact sensing. The ACT system is not currently approved for commercial use.

first wellness group

first wellness group is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AADCO Medical Inc

AADCO Medical Inc is a Randolph, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.

NeuSpera Medical

NeuSpera Medical will deliver a liberating alternative treatment for certain patients trapped by the symptoms of their disease.